Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 10/24 05:31:30 pm
230.7 CHF   -0.69%
10/24 ROCHE : LabCorp is first US laboratory to offer molecular testing wi..
10/21 SERVICES : data collection and recovery of a local tax.
10/21 ROCHE : F. Hoffmann-La Roche Announces Third Quarter Sales 2016
News SummaryMost relevantAll newsSector news 

Roche Holding Ltd. : Roche purchases shares in tender offer for Anadys Pharmaceuticals

share with twitter share with LinkedIn share with facebook
share via e-mail
11/23/2011 | 07:15am CEST

Basel, 23 November 2011

Roche purchases shares in tender offer for Anadys Pharmaceuticals

Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) at $3.70 per share in cash.

As of the expiration of the tender offer, a total of approximately 54,532,568 shares of Anadys common stock were tendered and not withdrawn (including approximately 2,345,764  shares tendered by delivery of notices of guaranteed delivery), representing approximately 94% of Anadys's outstanding shares.

Roche intends to complete the acquisition of Anadys through a short-form merger without a vote or meeting of Anadys's shareholders. In the merger, all shares of Anadys not owned by Anadys, Roche or their respective wholly owned subsidiaries (other than shares as to which appraisal rights are validly exercised) will be converted into the right to receive the same cash consideration per share as was paid in the tender offer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical Co., Ltd., Japan. For more information: www.roche.com.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements, including statements regarding the expected consummation of the acquisition, which involves a number of risks and uncertainties including the satisfaction of closing conditions for the acquisition such as regulatory approval for the transaction, the tender of a majority of the outstanding shares of common stock of Anadys and the possibility that the transaction will not be completed. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from any future statements. We generally identify these statements by words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," "should," "estimate," "predict," "potential," "continue," or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. The information contained in this press release is as of November 23, 2011. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Important Additional Information

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Anadys common stock. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) filed by Roche with the Securities and Exchange Commission (the "SEC") on October 25, 2011 [and subsequently amended]. These materials, as they may be further amended from time to time, contain important information, including the terms and conditions of the offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and Anadys's stockholders can obtain a free copy of these materials and other documents filed by Roche with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer materials may also be obtained for free by contacting the information agent for the tender offer, Mackenzie Partners at (212) 929-5500 (call collect) or (800) 322-2885 (toll-free) (USA).

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
10/24 ROCHE : LabCorp is first US laboratory to offer molecular testing with new fully..
10/21 SERVICES : data collection and recovery of a local tax.
10/21 ROCHE : F. Hoffmann-La Roche Announces Third Quarter Sales 2016
10/21 ISLET SCIENCES : Proven Pharma and Diagnostics Executive, Dr. Gary Blackburn, Jo..
10/20 ROCHE : Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies i..
10/20 CHARLES RIVER LABORATORIES INTL : Announces Extension of Integrated Discovery Pr..
10/20 ISLET SCIENCES : Proven Pharma and Diagnostics Executive, Dr. Gary Blackburn, Jo..
10/20 ROCHE : Swiss biotech company Roche posts 4 per cent sales growth
10/20 ROCHE : Swiss biotech company Roche posts 4 percent sales growth
More news
Sector news : Pharmaceuticals - NEC
10/24DJGLAXOSMITHKLINE : 3Q 2016 -- Forecast
10/24DJSyngenta and ChemChina Miss EU Deadline for Antitrust Remedies
10/24 GSK files potential $1 billion shingles vaccine for U.S. approval
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/21 PTC Therapeutics poised for $20M milestone from licensee Roche on advancement..
10/20 Roche Holding's (RHHBY) CEO Severin Schwan on Q3 2016 Results - Earnings Call..
10/20 Roche Holding Ltd ADR 2016 Q3 - Results - Earnings Call Slides
10/20 WALL STREET BREAKFAST : Saudi Arabia Issues $17.5B Worth Of Debt Amid High Deman..
10/20 Roche Holding ADR reports 9M results
Financials ( CHF)
Sales 2016 51 151 M
EBIT 2016 17 936 M
Net income 2016 11 372 M
Debt 2016 10 876 M
Yield 2016 3,69%
P/E ratio 2016 17,68
P/E ratio 2017 15,91
EV / Sales 2016 4,14x
EV / Sales 2017 3,86x
Capitalization 201 114 M
More Financials
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 293  CHF
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Daniel O'Day COO-Roche Pharmaceuticals Division
Roland Diggelmann COO-Roche Diagnostics Division
Alan Hippe Chief Financial & Information Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-15.88%202 361
JOHNSON & JOHNSON10.44%310 358
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results